Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H9NO3 |
Molecular Weight | 179.1727 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)NC1=CC=C(C=C1)C(O)=O
InChI
InChIKey=QCXJEYYXVJIFCE-UHFFFAOYSA-N
InChI=1S/C9H9NO3/c1-6(11)10-8-4-2-7(3-5-8)9(12)13/h2-5H,1H3,(H,10,11)(H,12,13)
DescriptionSources: https://www.medicines.org.uk/emc/medicine/27089Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/2431857
Sources: https://www.medicines.org.uk/emc/medicine/27089
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/2431857
Acedoben (4-acetamidobenzoic acid) is a benzoic acid derivative and a metabolite of benzocaine. It is a component of immunomodulatory drug inosine pranobex, which is used to treat mucocutaneous infections due to herpes simplex virus (type 1 and/or type II), genital warts as adjunctive therapy to podophyllin or carbon dioxide laser, and subacute sclerosing panencephalitis.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0006955 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2431857 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | IMUNOVIR Approved UseImunovir tablets are indicated in the management of mucocutaneous infections due to herpes simplex virus (type 1 and/or type II), genital warts as adjunctive therapy to podophyllin or carbon dioxide laser, and subacute sclerosing panencephalitis. Launch Date1983 |
|||
Primary | IMUNOVIR Approved UseImunovir tablets are indicated in the management of mucocutaneous infections due to herpes simplex virus (type 1 and/or type II), genital warts as adjunctive therapy to podophyllin or carbon dioxide laser, and subacute sclerosing panencephalitis. Launch Date1983 |
|||
Primary | IMUNOVIR Approved UseImunovir tablets are indicated in the management of mucocutaneous infections due to herpes simplex virus (type 1 and/or type II), genital warts as adjunctive therapy to podophyllin or carbon dioxide laser, and subacute sclerosing panencephalitis. Launch Date1983 |
PubMed
Title | Date | PubMed |
---|---|---|
Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. | 1986 Nov |
|
Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design. | 1997 Dec 5 |
|
Ellagic acid inhibited 2-aminofluorene and p-aminobenzoic acid acetylation by mononuclear leucocytes from Sprague-Dawley rats. | 2001 |
|
Effects of the butylated hydroxyanisole and butylated hydroxytoluene on the DNA adduct formation and arylamines N-acetyltransferase activity in human colon tumor cells. | 2001 Mar-Apr |
|
Toxicology and carcinogenesis studies of p-nitrotoluene (CAS no. 99-99-0) in F344/N rats and B6C3F(1) mice (feed studies). | 2002 May |
|
Metabolites of a blocked chloramphenicol producer. | 2003 Jan |
|
PCR and flow cytometric analysis of paclitaxel-inhibited arylamine N-acetyltransferase activity and gene expression in human osteogenic sarcoma cells (U-2 OS). | 2004 Jan-Feb |
|
Rhesus monkeys' valuation of vocalizations during a free-choice task. | 2009 Nov 18 |
|
Ambiguity aversion in rhesus macaques. | 2010 |
|
Striatal BOLD Response Reflects the Impact of Herd Information on Financial Decisions. | 2010 |
|
Following gaze: gaze-following behavior as a window into social cognition. | 2010 |
|
Coordinated scaling of cortical and cerebellar numbers of neurons. | 2010 |
|
Regioselective carboxylation of catechol by 3,4-dihydroxybenzoate decarboxylase of Enterobacter cloacae P. | 2010 May |
|
Immunomodulatory effects of inosine pranobex on cytokine production by human lymphocytes. | 2015 Jun |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.medicines.org.uk/emc/medicine/27089
Mucocutaneous herpes simplex: 1 g q.d.s. (4g daily), for 7 -14 days. Genital warts: 1g t.d.s. (3g daily), for 14-28 days as adjunctive therapy to podophyllin or carbon dioxide laser. Subacute sclerosing panencephalitis (SSPE): 50-100mg/kg daily, in divided does every 4 hours.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2431857
Inosine pranobex has been shown to stimulate various indices of metabolic activity of macrophages and monocytes. In vitro exposure to inosine pranobex or to 24-hour supernatants obtained from mononuclear cells pretreated with the drug restored chemotaxis to normal or near normal levels. Incubation with inosine pranobex in vitro stimulated the production of interleukin-l (lymphocyte activating factor) in human monocytes.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C73539
Created by
admin on Sat Dec 16 17:50:38 GMT 2023 , Edited by admin on Sat Dec 16 17:50:38 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
209-114-7
Created by
admin on Sat Dec 16 17:50:38 GMT 2023 , Edited by admin on Sat Dec 16 17:50:38 GMT 2023
|
PRIMARY | |||
|
CHEMBL112687
Created by
admin on Sat Dec 16 17:50:38 GMT 2023 , Edited by admin on Sat Dec 16 17:50:38 GMT 2023
|
PRIMARY | |||
|
4002
Created by
admin on Sat Dec 16 17:50:38 GMT 2023 , Edited by admin on Sat Dec 16 17:50:38 GMT 2023
|
PRIMARY | |||
|
ACEDOBEN
Created by
admin on Sat Dec 16 17:50:38 GMT 2023 , Edited by admin on Sat Dec 16 17:50:38 GMT 2023
|
PRIMARY | |||
|
SUB05203MIG
Created by
admin on Sat Dec 16 17:50:38 GMT 2023 , Edited by admin on Sat Dec 16 17:50:38 GMT 2023
|
PRIMARY | |||
|
C74109
Created by
admin on Sat Dec 16 17:50:38 GMT 2023 , Edited by admin on Sat Dec 16 17:50:38 GMT 2023
|
PRIMARY | |||
|
DTXSID5024392
Created by
admin on Sat Dec 16 17:50:38 GMT 2023 , Edited by admin on Sat Dec 16 17:50:38 GMT 2023
|
PRIMARY | |||
|
DB04500
Created by
admin on Sat Dec 16 17:50:38 GMT 2023 , Edited by admin on Sat Dec 16 17:50:38 GMT 2023
|
PRIMARY | |||
|
556-08-1
Created by
admin on Sat Dec 16 17:50:38 GMT 2023 , Edited by admin on Sat Dec 16 17:50:38 GMT 2023
|
PRIMARY | |||
|
19266
Created by
admin on Sat Dec 16 17:50:38 GMT 2023 , Edited by admin on Sat Dec 16 17:50:38 GMT 2023
|
PRIMARY | |||
|
04Z20NMK31
Created by
admin on Sat Dec 16 17:50:38 GMT 2023 , Edited by admin on Sat Dec 16 17:50:38 GMT 2023
|
PRIMARY | |||
|
46171
Created by
admin on Sat Dec 16 17:50:38 GMT 2023 , Edited by admin on Sat Dec 16 17:50:38 GMT 2023
|
PRIMARY | |||
|
100000087909
Created by
admin on Sat Dec 16 17:50:38 GMT 2023 , Edited by admin on Sat Dec 16 17:50:38 GMT 2023
|
PRIMARY | |||
|
4688
Created by
admin on Sat Dec 16 17:50:38 GMT 2023 , Edited by admin on Sat Dec 16 17:50:38 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)